BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Revdofilimab readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Revdofilimab\, from ClinicalTrials.gov es
 timates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT03893955-2081@assetmemo.bio
DTSTAMP:20261121T005354Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Revdofilimab: Phase 1 readout est. (NCT03893955)
DESCRIPTION:Revdofilimab\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: A 
 Study to Determine the Safety\, Tolerability\, Pharmacokinetics\, and Prel
 iminary Efficacy of ABBV-927 With ABBV-368\, Budigalimab (ABBV-181) and/or
  Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tu
 mors\nEstimated primary completion: March 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/revdofilimab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT03893955
URL:https://assetmemo.bio/drug/revdofilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
